APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Outlook and Growth Opportunities 2026

Report ID 174004690429 December 2025199 pages

Choose your research edition.

Industry ResearchIrritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market include Allergan, Amneal Pharms, Astellas Pharmaceuticals, Bausch Health, Sebela Pharmaceuticals and Pharscin Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Company

Allergan

Amneal Pharms

Astellas Pharmaceuticals

Bausch Health

Sebela Pharmaceuticals

Pharscin Pharma

Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Type

XIFAXAN

Lotronex

Viberzi

Other

Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Application

Hospitals Pharmacy

Retail Pharmacy

Other

Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs industry.

Chapter 3: Detailed analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Trends Table 2. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Drivers Table 3. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Opportunities and Challenges Table 4. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Restraints Table 5. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Company (2021-2026) Table 7. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Company (K Pcs) & (2021-2026) Table 8. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price (US$/Pcs) of Company (2021-2026) Table 10. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Company, Product Type & Application Table 13. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of XIFAXAN Table 18. Significant Companies of Lotronex Table 19. Significant Companies of Viberzi Table 20. Significant Companies of Other Table 21. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Pcs) Table 22. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Type (2021-2026) & (K Pcs) Table 23. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Type (2027-2032) & (K Pcs) Table 24. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Share by Type (2021-2026) Table 25. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Share by Type (2027-2032) Table 26. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type (2021-2026) Table 30. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospitals Pharmacy Table 32. Significant Companies of Retail Pharmacy Table 33. Significant Companies of Other Table 34. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Pcs) Table 35. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Application (2021-2026) & (K Pcs) Table 36. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Application (2027-2032) & (K Pcs) Table 37. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Share by Application (2021-2026) Table 38. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Share by Application (2027-2032) Table 39. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application (2021-2026) Table 43. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application (2027-2032) Table 44. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Pcs) Table 45. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2021-2026) & (K Pcs) Table 46. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2021-2026) Table 47. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2027-2032) & (K Pcs) Table 48. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2027-2032) Table 49. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Region (2021-2026) Table 52. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Region (2027-2032) Table 54. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Average Price (US$/Pcs) by Region (2021-2026) Table 55. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Average Price (US$/Pcs) by Region (2027-2032) Table 56. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Pcs) Table 57. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021-2026) & (K Pcs) Table 59. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2021-2026) Table 60. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2027-2032) & (K Pcs) Table 61. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2027-2032) Table 62. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Market Share by Country (2021-2026) Table 64. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Market Share by Country (2027-2032) Table 66. Allergan Company Information Table 67. Allergan Business Overview Table 68. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 69. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio Table 70. Allergan Recent Development Table 71. Amneal Pharms Company Information Table 72. Amneal Pharms Business Overview Table 73. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 74. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio Table 75. Amneal Pharms Recent Development Table 76. Astellas Pharmaceuticals Company Information Table 77. Astellas Pharmaceuticals Business Overview Table 78. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 79. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio Table 80. Astellas Pharmaceuticals Recent Development Table 81. Bausch Health Company Information Table 82. Bausch Health Business Overview Table 83. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 84. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio Table 85. Bausch Health Recent Development Table 86. Sebela Pharmaceuticals Company Information Table 87. Sebela Pharmaceuticals Business Overview Table 88. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 89. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio Table 90. Sebela Pharmaceuticals Recent Development Table 91. Pharscin Pharma Company Information Table 92. Pharscin Pharma Business Overview Table 93. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 94. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio Table 95. Pharscin Pharma Recent Development Table 96. Key Raw Materials Table 97. Raw Materials Key Suppliers Table 98. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors List Table 99. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customers List Table 100. Research Programs/Design for This Report Table 101. Authors List of This Report Table 102. Secondary Sources Table 103. Primary Sources List of Figures Figure 1. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Image Figure 2. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (2021-2032) & (K Pcs) Figure 5. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Average Price (US$/Pcs) & (2021-2032) Figure 6. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. XIFAXAN Image Figure 10. Lotronex Image Figure 11. Viberzi Image Figure 12. Other Image Figure 13. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Pcs) Figure 14. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Share by Type (2021-2032) Figure 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type (2021-2032) Figure 19. Hospitals Pharmacy Image Figure 20. Retail Pharmacy Image Figure 21. Other Image Figure 22. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Pcs) Figure 23. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Share by Application (2021-2032) Figure 25. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application (2021-2032) Figure 28. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Pcs) Figure 29. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • XIFAXAN
  • Lotronex
  • Viberzi
  • Other
Applications
  • Hospitals Pharmacy
  • Retail Pharmacy
  • Other
Companies covered
  • Allergan
  • Amneal Pharms
  • Astellas Pharmaceuticals
  • Bausch Health
  • Sebela Pharmaceuticals
  • Pharscin Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Dynamics
  1. 2.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Trends
  2. 2.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Drivers
  3. 2.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Opportunities and Challenges
  4. 2.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Restraints
3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Company
  1. 3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Company Ranking (2024-2026)
  6. 3.6 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Company Product Type and Application
  8. 3.8 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Type
  1. 4.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Type Introduction
  2. 4.1.1 XIFAXAN
  3. 4.1.2 Lotronex
  4. 4.1.3 Viberzi
  5. 4.1.4 Other
  6. 4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Type
  7. 4.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Type
  11. 4.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Type (2021-2032)
  13. 4.3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type (2021-2032)
5 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Application
  1. 5.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Application Introduction
  2. 5.1.1 Hospitals Pharmacy
  3. 5.1.2 Retail Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Application
  6. 5.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Application
  10. 5.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application (2021-2032)
6 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Regional Sales and Value Analysis
  1. 6.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2027-2032)
  5. 6.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Country, 2025 VS 2032
7 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2027-2032)
  6. 7.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Allergan
  2. 8.1.1 Allergan Company Information
  3. 8.1.2 Allergan Business Overview
  4. 8.1.3 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
  6. 8.1.5 Allergan Recent Developments
  7. 8.2 Amneal Pharms
  8. 8.2.1 Amneal Pharms Company Information
  9. 8.2.2 Amneal Pharms Business Overview
  10. 8.2.3 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
  12. 8.2.5 Amneal Pharms Recent Developments
  13. 8.3 Astellas Pharmaceuticals
  14. 8.3.1 Astellas Pharmaceuticals Company Information
  15. 8.3.2 Astellas Pharmaceuticals Business Overview
  16. 8.3.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
  18. 8.3.5 Astellas Pharmaceuticals Recent Developments
  19. 8.4 Bausch Health
  20. 8.4.1 Bausch Health Company Information
  21. 8.4.2 Bausch Health Business Overview
  22. 8.4.3 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
  24. 8.4.5 Bausch Health Recent Developments
  25. 8.5 Sebela Pharmaceuticals
  26. 8.5.1 Sebela Pharmaceuticals Company Information
  27. 8.5.2 Sebela Pharmaceuticals Business Overview
  28. 8.5.3 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
  30. 8.5.5 Sebela Pharmaceuticals Recent Developments
  31. 8.6 Pharscin Pharma
  32. 8.6.1 Pharscin Pharma Company Information
  33. 8.6.2 Pharscin Pharma Business Overview
  34. 8.6.3 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
  36. 8.6.5 Pharscin Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Chain Analysis
  2. 9.1.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Mode & Process
  6. 9.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors
  9. 9.2.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst